SRP-9001 - Emerging Insight and Market Forecast - 2030

The report provides comprehensive insights about an investigational product for Duchene muscular dystrophy (DMD) in 7 Major Markets. A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

SRP-9001 is being developed by Sarepta Therapeutics which is currently in Phase II clinical development for the treatment of Duchenne muscular dystrophy. It is designed to deliver the micro-dystrophin-encoding gene directly to the muscle tissue for the targeted production of the micro-dystrophin protein. Roche has acquired exclusive commercial rights outside the United States to Sarepta Therapeutics’ lead gene therapy pipeline candidate SRP-9001 for Duchenne muscular dystrophy (DMD)

Scope of the report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SRP-9001.
• The report contains forecasted sales for SRP-9001 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Duchene muscular dystrophy.
• The report also features the SWOT analysis with analyst insights and key findings of SRP-9001.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SRP-9001 Analytical Perspective

In-depth SRP-9001 Market Assessment

This report provides a detailed market assessment of SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

SRP-9001 Clinical Assessment

The report provides the clinical trials information of SRP-9001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Duchene muscular dystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence SRP-9001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Duchene muscular dystrophy are giving market competition to SRP-9001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SRP-9001.
• Our in-depth analysis of the forecasted sales data of SRP-9001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SRP-9001.

Key Questions Answered

• Which company is developing SRP-9001 along with the phase of the clinical study?
• Which technology utilized in the development of SRP-9001?
• What is the product type, route of administration and mechanism of action of SRP-9001?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SRP-9001 development?
• What are the key designations that have been granted to SRP-9001?
• What is the forecasted market scenario of SRP-9001?
• What is the history of SRP-9001 and what is its future?
• What is the forecasted sales of SRP-9001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to SRP-9001?
• Which are the late-stage emerging therapies under development for the treatment of the AMD?